Bournaud C, et al. - In this prospective observational study including a series of 173 intermediate- to high-risk patients with thyroid cancer, researchers examined the link between TERT promoter mutations and recurrence. Participants were tested for TERT promoter, BRAF, and RAS mutations of their primary tumours. TERT promoter mutations prevailed in 20.2% (35/173) participants and a significantly higher prevalence was seen in tumours harbouring aggressive histological features (poorly differentiated carcinoma, tall cell variant of papillary cancer or widely invasive follicular cancer) vs non-aggressive tumours. A strong association of TERT promoter mutations was seen with age ≥45 years, pT4 stage, metastatic disease, and extrathyroidal extension. In the overall population, poor outcomes were noted in association with TERT promoter mutations. However, they were found to be related to a worse outcome in patients both free of metastases and devoid of aggressive histological features. Overall, TERT promoter mutations could aid to better define the prognosis of localized thyroid cancer patients without aggressive histology, however, their prognostic value did not appear to overcome that of histology.